Watch PLX. Know when insiders buy.
One email the day a filing lands. Free.
PLX
Protalix BioTherapeutics, Inc.
2.72
−0.03 −1.09%
USD · close Sep 25
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
82
PASS · shorts 82
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $219.2MP/E 11.8DIV YIELD —FCF YIELD 3.50%REV TTM $80.6M +30.1%NET INCOME $18.9M +201.9%NET CASH $26.5M52W 1.67 – 3.15SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $19.9M | +27.1% | 61.0% | $4.7M | $3.8M | +2203.0% | 0.05 | −$10.4M | $593K | −$11M | Aug 12 |
| Q1 2026 · Mar 31 | $33.8M | +233.7% | 87.8% | $21.1M | $18.3M | — | 0.22 | $22M | $761K | $21.3M | May 13 |
| Q4 2025 · Dec 31derived | $9.1M | −49.9% | 49.4% | −$4.7M | −$5.5M | −184.8% | -0.07 | $2M | $403K | $1.6M | Mar 18 |
| Q3 2025 · Sep 30 | $17.9M | −0.6% | 53.4% | $2.1M | $2.4M | −27.2% | 0.03 | −$3.7M | $498K | −$4.2M | Nov 13 |
| Q2 2025 · Jun 30 | $15.7M | +16.2% | 62.5% | $1.2M | $164K | — | 0.00 | −$5.2M | $431K | −$5.7M | Aug 12 |
| Q1 2025 · Mar 31 | $10.1M | +169.8% | 19.1% | −$4.1M | −$3.6M | — | -0.05 | −$5.1M | $306K | −$5.4M | May 13 |
| Q4 2024 · Dec 31derived | $18.2M | +73.7% | 78.7% | $7.2M | $6.5M | — | 0.09 | $4M | $425K | $3.6M | Mar 18 |
| Q3 2024 · Sep 30 | $18M | +73.6% | 53.4% | $4M | $3.2M | — | 0.03 | $4.1M | $87K | $4M | Nov 13 |
| Q2 2024 · Jun 30 | $13.5M | — | 29.8% | −$2.4M | −$2.2M | — | -0.03 | −$3.6M | $172K | −$3.8M | Aug 14 |
| Q1 2024 · Mar 31 | $3.7M | — | 30.6% | −$4.9M | −$4.6M | — | -0.06 | $4.2M | $598K | $3.6M | May 9 |
| Q4 2023 · Dec 31derived | $10.5M | — | 15.5% | −$5.6M | −$6M | — | -0.07 | $3.6M | $250K | $3.3M | Mar 18 |
| Q3 2023 · Sep 30 | $10.3M | — | 52.7% | −$1.9M | −$1.9M | — | -0.04 | −$6.9M | $447K | −$7.3M | Nov 14 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $52.7M | 48.8% | −$5.5M | −$6.6M | -12.5% | -0.08 | −$12M | $1.6M | −$13.6M | — | — |
| FY2024 · to Dec 31 | $53.4M | 54.5% | $3.9M | $2.9M | 5.5% | 0.04 | $8.7M | $1.3M | $7.4M | — | — |
| FY2023 · to Dec 31 | $65.5M | 64.9% | $10.5M | $8.3M | 12.7% | 0.09 | −$1.3M | $1.1M | −$2.5M | — | — |
| FY2022 · to Dec 31 | $47.6M | 58.9% | −$13M | −$14.9M | -31.3% | -0.31 | −$25M | $628K | −$25.6M | — | — |
| FY2021 · to Dec 31 | $38.4M | 57.4% | −$20.5M | −$27.6M | -71.9% | -0.62 | −$10.3M | $1.5M | −$11.7M | — | — |
| FY2020 · to Dec 31 | $62.9M | 82.7% | $2.7M | −$6.5M | -10.4% | -0.22 | −$26.1M | $655K | −$26.8M | — | — |
Every number comes from Protalix BioTherapeutics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.